Key result
This review discusses the interplay between pharmacology and genetics of cardiac ion channels in the causation and treatment of cardiac arrhythmias, focusing on long QT syndromes.
This review highlights the role of pharmacogenetics in understanding and managing drug-induced arrhythmias, particularly long QT syndromes.
May inform pharmacogenetic approaches to long QT management; leaves open prospective validation before clinical adoption.
Abnormal functioning of cardiac ion channels can disrupt cardiac myocyte action potentials and thus cause potentially lethal cardiac arrhythmias. Ion channel dysfunction has been observed at all stages in channel ontogeny, from biogenesis to regulation, and arises from genetic or environmental factors, or both. Acquired arrhythmias - including those that are drug induced - are more common than solely inherited arrhythmias but, in some cases, also contain an identifiable genetic component. This interplay between the pharmacology and genetics - known as 'pharmacogenetics' - of cardiac ion channels and the systems that impact them presents both challenges and opportunities to academics, pharmaceutical companies and clinicians seeking to develop and utilize therapies for cardiac rhythm disorders. In this review, we discuss ion channel pharmacogenetics in the context of both causation and treatment of cardiac arrhythmias, focusing on the long QT syndromes.
No takes yet. Share an insight, caveat, or question.
Abbott et al. (2008) conducted a review in Drug-induced arrhythmias and long QT syndromes. Pharmacogenetics was evaluated. This review discusses the interplay between pharmacology and genetics of cardiac ion channels in the causation and treatment of cardiac arrhythmias, focusing on long QT syndromes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: